• Advert Rates
  • Careers
  • About Us
  • Contact Us
  • Digital Store
Friday, May 22, 2026
The Trumpet Newspaper Nigeria
No Result
View All Result
  • Home
  • News
    • Breaking News
    • Headlines
    • Metro
    • Health
  • Politics
  • Business
    • Ecommerce
    • Economy
    • Start-up
  • Entertainment
  • Sports
  • Opinion
    • Religion
    • Columnists
    • Contributors
    • Editorial
  • Global
    • Climate
    • Culture
    • Tourism
    • Technology
    • Weather
    • Social Media
  • e-Edition
  • Home
  • News
    • Breaking News
    • Headlines
    • Metro
    • Health
  • Politics
  • Business
    • Ecommerce
    • Economy
    • Start-up
  • Entertainment
  • Sports
  • Opinion
    • Religion
    • Columnists
    • Contributors
    • Editorial
  • Global
    • Climate
    • Culture
    • Tourism
    • Technology
    • Weather
    • Social Media
  • e-Edition
No Result
View All Result
The Trumpet Newspaper Nigeria
No Result
View All Result
ADVERTISEMENT
Home News

Cross River begins administering Lenacapavir injectable to curb new HIV infections

Inyang Inyang by Inyang Inyang
May 22, 2026
in News
Reading Time: 4 mins read
0
Cross River begins administering Lenacapavir injectable to curb new HIV infections
0
SHARES
14
VIEWS
Share on FacebookShare on TwitterShare on LinkedinShare on WhatsAppShare on Pinterest

In an efforts to curb new HIV infections and improve public health outcomes, the Cross River State government has launched the Lenacapavir Injectable Pre-Exposure Prophylaxis (PrEP), a long-acting HIV prevention intervention in Calabar.

Lenacapavir provides up to 99 percent protection against HIV infection when used as a preventive therapy

ADVERTISEMENT

Key Highlights:

  • The Cross River State government has launched Lenacapavir injectable PrEP to prevent new HIV infections.
  • The drug offers up to 99% protection and is administered twice yearly, improving convenience and adherence.
  • Health officials say the initiative is part of a pilot programme in eight Nigerian states to strengthen HIV prevention.
  • The programme targets vulnerable groups, including adolescents and key populations, while emphasizing that it does not prevent other STIs or pregnancy.
  • Authorities, including the State Agency for the Control of AIDS (SACA), warned that the drug is free and must not be sold.

Unlike daily oral medications, Lenacapavir provides a long-acting preventive option administered twice yearly, improving adherence, privacy and convenience for vulnerable persons at risk of HIV infection

Speaking during the launch, the Commissioner for Health, Dr. Henry Ayuk, represented by the Permanent Secretary of the ministry, Dr Jonah Offor, described the initiative as a significant milestone in the global fight against HIV/AIDS.

Read Also:

  • Leaders of Cross River warring communities reach agreement to sanction erring traditional rulers
  • Cross River Police Command launches new tactical outfit to combat crime
  • APC national treasurer tasks Cross River chapter on aggressive voter mobilization ahead 2027 polls

He said Cross River State is among eight states selected for the pilot phase of the intervention, adding that the introduction of Lenacapavir reflects the commitment of the administration of Governor Bassey Otu to innovative and people-centred healthcare delivery.

According to him, prevention remains safer and more cost-effective than treatment.

Programme Manager of the Cross River State AIDS, Viral Hepatitis and STIs Control Programme, Mary-Treasure Amah, described Lenacapavir as a “game changer,” the power of science meeting the needs of people in HIV prevention strategies in Nigeria.

She explained that the injectable PrEP would reduce stigma, lessen pill burden and expand prevention choices, especially for adolescents, young people and key populations.

However, she cautioned that the intervention should not be misconstrued as promoting promiscuity, since it does not prevent pregnancy or other sexually transmitted infections.

According to the permanent secretary, facilities selected for the pilot rollout of the Lenacapavir PrEP injection in Cross River State include, the University of Calabar Teaching Hospital, General Hospital, Calabar, General Hospital, Akamkpa, General Hospital, Ugep, Cottage Hospital, Akpet in Biase Local Government Area, and the One-Stop Shop (OSS) in Bakassi.

The Cross River State Coordinator of the World Health Organization (WHO), Dr. Yewande Olatunde, described the initiative as a strategic approach to reducing HIV prevalence, noting that Africa still bears about 65 percent of the global HIV burden.

She urged implementers in the state to ensure proper data management and effective deployment of the intervention to justify the state’s inclusion among the pilot states.

Also speaking, the Director General of the Cross River State Agency for the Control of AIDS (SACA), Dr. Charles Iwara, disclosed that the Global Fund strongly backed Cross River’s inclusion among the eight pilot states because of its commitment to HIV response programmes.

Iwara, warned against the sale of the drug since it is meant to be administered free of charge to eligible persons.

Previous Post

Manchester City confirm Guardiola’s departure at end of season

Next Post

Saudi Arabia holds military parade to showcase emergency response drills ahead of 2026 Hajj

Inyang Inyang

Inyang Inyang

Next Post
Saudi Arabia holds military parade to showcase emergency response drills ahead of 2026 Hajj

Saudi Arabia holds military parade to showcase emergency response drills ahead of 2026 Hajj

About The Trumpet

The Trumpet is a Nigerian based national news media, owned, trademarked and operated by Elomaz Communications Limited with headquarters in FCT-Abuja and regional offices in Lagos and Delta States

Follow Us

Resources

  • Home
  • News
    • Breaking News
    • Headlines
    • Metro
    • Health
  • Politics
  • Business
    • Ecommerce
    • Economy
    • Start-up
  • Entertainment
  • Sports
  • Opinion
    • Religion
    • Columnists
    • Contributors
    • Editorial
  • Global
    • Climate
    • Culture
    • Tourism
    • Technology
    • Weather
    • Social Media
  • e-Edition

Recent News

EEDC completes billing system integration, goes live with SuperEdge

EEDC completes billing system integration, goes live with SuperEdge

May 22, 2026
Court dismisses suit seeking to stop Sen. Kingibe from participating in ADC activities

Court dismisses suit seeking to stop Sen. Kingibe from participating in ADC activities

May 22, 2026
  • Cookie Policy
  • Disclaimer
  • Contact us
  • About Us
  • Cookie Policy
  • Disclaimer
  • Contact us
  • About Us

© 2025 The Trumpet News Papers - Developed by VIS Nigeria.

No Result
View All Result
  • Home
  • News
    • Breaking News
    • Headlines
    • Metro
    • Health
  • Politics
  • Business
    • Ecommerce
    • Economy
    • Start-up
  • Entertainment
  • Sports
  • Opinion
    • Religion
    • Columnists
    • Contributors
    • Editorial
  • Global
    • Climate
    • Culture
    • Tourism
    • Technology
    • Weather
    • Social Media
  • e-Edition

© 2025 The Trumpet News Papers - Developed by VIS Nigeria.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT